These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24384177)

  • 1. Invited commentary.
    Bhorade S
    Ann Thorac Surg; 2014 Jan; 97(1):274-5. PubMed ID: 24384177
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
    Sacher VY; Fertel D; Srivastava K; Panos A; Nguyen D; Baxter T; Shafazand S; Pham SM
    Ann Thorac Surg; 2014 Jan; 97(1):268-74. PubMed ID: 24119986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttransplant bronchiolitis obliterans syndrome. Where have we been and where are we going?
    Dauber JH
    Chest; 1996 Apr; 109(4):857-9. PubMed ID: 8635356
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival after bronchiolitis obliterans syndrome.
    Yerkovich ST; Hopkins PM; Chambers DC
    Am J Respir Crit Care Med; 2011 Feb; 183(4):554; author reply 554-5. PubMed ID: 21325085
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation.
    Speich R; Schneider S; Hofer M; Irani S; Vogt P; Weder W; Boehler A
    Pulm Pharmacol Ther; 2010 Oct; 23(5):445-9. PubMed ID: 20394831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.
    Groetzner J; Wittwer T; Kaczmarek I; Ueberfuhr P; Strauch J; Nagib R; Meiser B; Franke U; Reichart B; Wahlers T
    Transplantation; 2006 Feb; 81(3):355-60. PubMed ID: 16477220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation.
    Bhorade S; Ahya VN; Baz MA; Valentine VG; Arcasoy SM; Love RB; Seethamraju H; Alex CG; Bag R; Deoliveira NC; Husain A; Vigneswaran WT; Charbeneau J; Krishnan JA; Durazo-Arvizu R; Norwick L; Garrity E
    Am J Respir Crit Care Med; 2011 Feb; 183(3):379-87. PubMed ID: 20833822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of bronchiolitis obliterans in allogeneic rat lung transplantation--effectiveness of everolimus.
    von Suesskind-Schwendi M; Brunner E; Hirt SW; Diez C; Ruemmele P; Puehler T; Schmid C; Lehle K
    Exp Toxicol Pathol; 2013 May; 65(4):383-9. PubMed ID: 22284335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo.
    Nair RV; Huang X; Shorthouse R; Adams B; Brazelton T; Braun-Dullaeus R; Morris RE
    Transplant Proc; 1997; 29(1-2):614-5. PubMed ID: 9123154
    [No Abstract]   [Full Text] [Related]  

  • 10. Proceedings of the Vth International Alexis Carrel Conference. Genesis, prevention, diagnosis and treatment of chronic rejection, obliterative bronchiolitis and graft vessel disease after organ transplantation. Munich, Germany, June 22-24, 1994.
    Transplant Proc; 1995 Jun; 27(3):i-iii, 1921-2136. PubMed ID: 7792837
    [No Abstract]   [Full Text] [Related]  

  • 11. Advantage--FK 506: reduced chronic rejection for lung transplant recipients.
    Bolman RM
    Ann Thorac Surg; 1995 Sep; 60(3):495-6. PubMed ID: 7545888
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung-resident mesenchymal stromal cells. A new player in post-transplant bronchiolitis obliterans syndrome?
    Martinu T; Palmer SM; Ortiz LA
    Am J Respir Crit Care Med; 2011 Apr; 183(8):968-70. PubMed ID: 21498820
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction therapy in lung transplantation.
    Sweet SC
    Transpl Int; 2013 Jul; 26(7):696-703. PubMed ID: 23701023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation.
    Glanville AR; Aboyoun CL; Morton JM; Plit M; Malouf MA
    J Heart Lung Transplant; 2006 Aug; 25(8):928-34. PubMed ID: 16890113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The macrolide clarithromycin inhibits experimental post-transplant bronchiolitis obliterans.
    Remund K; Rechsteiner T; Guo Z; Rentsch K; Boehler A
    Exp Lung Res; 2009 Dec; 35(10):830-40. PubMed ID: 19995277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus in lung transplantation in Chile.
    Parada MT; Alba A; Sepúlveda C
    Transplant Proc; 2010; 42(1):328-30. PubMed ID: 20172343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update in transplantation 2007.
    Corris PA; Christie JD
    Am J Respir Crit Care Med; 2008 May; 177(10):1062-7. PubMed ID: 18460461
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients.
    McNeil K; Glanville AR; Wahlers T; Knoop C; Speich R; Mamelok RD; Maurer J; Ives J; Corris PA
    Transplantation; 2006 Apr; 81(7):998-1003. PubMed ID: 16612275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obliterative bronchiolitis: prevention.
    Kallio EA; Koskinen PK; Tikkanen JM; Lemström KB
    Transplant Proc; 2001; 33(1-2):1617-9. PubMed ID: 11267443
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapamycin and chronic lung rejection.
    Ussetti P; Carreño MC; de Pablo A; Gamez P; Varela A
    J Heart Lung Transplant; 2004 Jul; 23(7):917-8. PubMed ID: 15261192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.